Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Researchers recently completed a 16-week phase 2b trial for patients with ulcerative colitis.
While current testing has largely focused on ulcerative colitis, researchers believe ABX464 could also show some promise treating Crohn’s disease as well.
Researchers from Abivax, recently completed a 16-week phase 2b trial testing different doses of the drug against a placebo for ulcerative colitis patients.
ABX464 is a novel, orally administrated small molecule that could treat ulcerative colitis by interacting with CBC, allowing specific splicing of anti-inflammatory miR-124, leading to a cascade of modulating pro-inflammatory cytokines.
ABX464 has also demonstrated a dual mechanisms of action in HIV by generating miR-124 and splicing viral RNA that shows promise in its ability to treat inflammatory bowel disease (IBD).
The trial focused on 25, 50, and 100 mg of ABX464 in 130 study centers in the US, Canada, and 15 European countries with more than 800 patients across different indications, including ulcerative colitis.
In an interview with HCPLive®, Hartmut J. Ehrlich, MD, CEO of Abivax and Philippe Pouletty, MD, chairman of the board of directors at Abivax, explained how promising the treatment is and what the future plans for the ABX464 are.
The researchers said while it is unlikely the treatment would move to the first option for ulcerative colitis, it is very likely ABX464 would be considered a second or third option for patients.